Cargando…

Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the (213)Bi-labeled monoclonal antibody MX35 in an ovarian cancer model

BACKGROUND: The aim of this study was to compare the therapeutic efficacy of two different activity levels of the (213)Bi-labeled monoclonal antibody MX35 in an ovarian cancer model. Sixty female BALB/c (nu/nu) mice were inoculated intraperitoneally with human ovarian cancer cells (OVCAR-3). Two wee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gustafsson-Lutz, Anna, Bäck, Tom, Aneheim, Emma, Hultborn, Ragnar, Palm, Stig, Jacobsson, Lars, Morgenstern, Alfred, Bruchertseifer, Frank, Albertsson, Per, Lindegren, Sture
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403775/ https://www.ncbi.nlm.nih.gov/pubmed/28439844 http://dx.doi.org/10.1186/s13550-017-0283-2

Ejemplares similares

Evaluation of therapeutic efficacy of (211)At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer
por: Palm, Stig, et al.
Publicado: (2020)

Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200
por: Lindegren, Sture, et al.
Publicado: (2015)

Estimating the Risk for Secondary Cancer After Targeted α-Therapy with (211)At Intraperitoneal Radioimmunotherapy
por: Leidermark, Erik, et al.
Publicado: (2023)

Automated astatination of biomolecules – a stepping stone towards multicenter clinical trials
por: Aneheim, Emma, et al.
Publicado: (2015)

Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure
por: Lindegren, Sture, et al.
Publicado: (2020)

Repeated Intraperitoneal α-Radioimmunotherapy of Ovarian Cancer in Mice
por: Elgqvist, Jörgen, et al.
Publicado: (2010)

Towards elucidating the radiochemistry of astatine – Behavior in chloroform
por: Aneheim, Emma, et al.
Publicado: (2019)

Astatine-211 based radionuclide therapy: Current clinical trial landscape
por: Albertsson, Per, et al.
Publicado: (2023)

Radioimmunotherapy of micrometastases in lung with vascular targeted(213)Bi
por: Kennel, S J, et al.
Publicado: (1999)

α-Radioimmunotherapy with (213)Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma
por: Teiluf, Katharina, et al.
Publicado: (2014)

Successful radioimmunotherapy of established syngeneic rat colon carcinoma with (211)At-mAb
por: Eriksson, Sophie E, et al.
Publicado: (2013)

First‐Generation Bispidine Chelators for (213)Bi(III) Radiopharmaceutical Applications
por: Bruchertseifer, Frank, et al.
Publicado: (2020)

Pretargeted Alpha Therapy of Disseminated Cancer Combining Click Chemistry and Astatine-211
por: Timperanza, Chiara, et al.
Publicado: (2023)

Radium and Francium beam tests to produce 225Ac/ 213Bi generators at CERN-MEDICIS
por: Bruchertseifer, Frank, et al.
Publicado: (2015)

Long-Term Toxicity of (213)Bi-Labelled BSA in Mice
por: Dorso, Laëtitia, et al.
Publicado: (2016)

Diverse metabolic response of cancer cells treated with a (213)Bi-anti-EGFR-immunoconjugate
por: Feuerecker, Benedikt, et al.
Publicado: (2021)

In Vitro comparison of (213)Bi- and (177)Lu-radiation for peptide receptor radionuclide therapy
por: Chan, Ho Sze, et al.
Publicado: (2017)

Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model
por: Fichou, Nolwenn, et al.
Publicado: (2015)

Supply and Clinical Application of Actinium-225 and Bismuth-213
por: Morgenstern, Alfred, et al.
Publicado: (2020)

Alpha-Particle Emitting (213)Bi-Anti-EGFR Immunoconjugates Eradicate Tumor Cells Independent of Oxygenation
por: Wulbrand, Christian, et al.
Publicado: (2013)

Efficient formation of inert Bi-213 chelates by tetraphosphorus acid analogues of DOTA: towards improved alpha-therapeutics
por: Šimeček, Jakub, et al.
Publicado: (2018)

Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b
por: Levan, Kristina, et al.
Publicado: (2017)

Assessment of (213)Bi-anti-EGFR MAb treatment efficacy in malignant cancer cells with [1-(13)C]pyruvate and [(18)F]FDG
por: Feuerecker, Benedikt, et al.
Publicado: (2019)

Optimizing labelling conditions of (213)Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapy
por: Chan, Ho Sze, et al.
Publicado: (2016)

Therapeutic Performance Evaluation of (213)Bi-Labelled Aminopeptidase N (APN/CD13)-Affine NGR-Motif ([(213)Bi]Bi-DOTAGA-cKNGRE) in Experimental Tumour Model: A Treasured Tailor for Oncology
por: Képes, Zita, et al.
Publicado: (2023)

Influence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0),Tyr(3)]-octreotate
por: Chan, Ho Sze, et al.
Publicado: (2016)

Intraperitoneal Alpha-Radioimmunotherapy of Advanced Ovarian Cancer in Nude Mice Using Different High Specific Activities
por: Elgqvist, Jorgen, et al.
Publicado: (2010)

An Overview of Targeted Alpha Therapy with (225)Actinium and (213)Bismuth
por: Morgenstern, Alfred, et al.
Publicado: (2018)

Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with (213)Bi-substance P analogue
por: Krolicki, Leszek, et al.
Publicado: (2018)

Cubosomal Lipid Formulation for Combination Cancer Treatment: Delivery of a Chemotherapeutic Agent and Complexed α-Particle Emitter (213)Bi
por: Cytryniak, Adrianna, et al.
Publicado: (2022)

Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors
por: Bäck, Tom A., et al.
Publicado: (2020)

Level structure in $^{213}Bi$
por: Chumin, V G, et al.
Publicado: (1996)

(213)Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
por: Kratochwil, C., et al.
Publicado: (2014)

Monoclonal Antibodies Radiolabeling with Rhenium-188 for Radioimmunotherapy
por: Uccelli, Licia, et al.
Publicado: (2017)

Therapeutic Efficacy of Alpha-RIT Using a (213)Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal Carcinomatosis
por: Derrien, Aurélie, et al.
Publicado: (2015)

Multifunctional Clickable Reagents for Rapid Bioorthogonal Astatination and Radio‐Crosslinking
por: Denk, Christoph, et al.
Publicado: (2019)

Comparative Radioimmunotherapy of Experimental Melanoma with Novel Humanized Antibody to Melanin Labeled with 213Bismuth and 177Lutetium
por: Allen, Kevin J. H., et al.
Publicado: (2019)

Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy.
por: Bosslet, K., et al.
Publicado: (1991)

Combining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction
por: Ménager, Jérémie, et al.
Publicado: (2015)

Treatment of Peritoneal Carcinomatosis by Targeted Delivery of the Radio-Labeled Tumor Homing Peptide (213)Bi-DTPA-[F3](2) into the Nucleus of Tumor Cells
por: Drecoll, Enken, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_oo3ka6lgp1i6v6foo6g9gs5svl